Sanofi share price today

Sanofi's share price was $47.47 at the close on 4 November 2026. It has been stalling near its high for 2 weeks. That is 7.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $40 and $52, and at that close it sat 62% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sanofi is in stage 3. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row.

Over the last 10 years the share price moved +16% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Sanofi declared EUR 4.12 per local share for Dec 2025. It reports in euros, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield.

Sanofi is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Sanofi earned EUR 377 M of net profit in the Jun 2026 quarter, −90.4% on the same quarter a year earlier. Full-year FY25 profit was EUR 7.9 B. Over 4 years profit has grown 5.7% a year on average. That is 3.1% of the quarter's revenue. The same quarter a year earlier earned EUR 3.9 B.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 11 reported quarters were loss-making.

For the full year, FY25 profit was EUR 7.9 B (+39.7% on the year before).

Why profit moved: revenue changed +14.6% on a year earlier and the margin moved +5.1 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed −35.4% and revenue +4.5%. Profit is growing slower than sales: rising costs are taking part of the growth.

This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted.

Sanofi reported EUR 12.3 B of revenue in the Jun 2026 quarter, +14.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 4.5% a year on average. The last full year, FY25, came in at EUR 46.7 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to EUR 48.9 B.

The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums.

FY25 revenue was EUR 46.7 B, +5.5% on the year before.

Recent pace: the last four quarters grew +4.5% on average, against 4.5% a year over the longer run, so this year is growing at about the same pace as its own long-run rate.

This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted.

Sanofi's operating margin was 21.0% in the Jun 2026 quarter, 5.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 19.8% and 25.8%. The latest quarter is within that range.

Operating margin is what is left from every EUR 100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +5.1 percentage points on the year while gross margin changed +4.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 159% of Sanofi's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in EUR 10.8 B of operating cash against EUR 7.9 B of profit. After EUR 1.8 B of spending on assets, EUR 9.0 B was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted.

Sanofi does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent EUR 5.1 B on assets over the last 3 years. Averaged over those years that is 3.6% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: EUR 5.1 B over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted.

Sanofi's P/E is 24.4×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Sanofi's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Sanofi earned a ROE of 11% in FY25. That is up from a low of 7% in FY24. Its return on capital used (ROIC) is 3.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 16.8% net margin and 0.37× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 16.8% net margin × 0.37× asset turnover × 1.77× leverage (assets divided by equity) ≈ 11.0% on equity. The margin does most of the work; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 9.0% − 5.2% = +3.8 percentage points. The 5.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

Sanofi has total debt of EUR 23.6 B against shareholder equity of EUR 69.6 B as of Jun 2026, so its debt is 0.34× its equity. Year by year, that ratio went from 0.32 in FY21 to 0.28 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted.

1.1% of Sanofi's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 3.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Sanofi, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

51.4 out of 100, rank 7 of 16 in Drug Manufacturers - General, with 66% of the evidence available.

Sanofi scores 51.4 out of 100 against the 16 companies it is compared with in Drug Manufacturers - General, ranking 7. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 20.6 + 9.2 + 14.3 + 7.3 = 51.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Sanofi ranks 7 of 16 Drug Manufacturers - General companies on the 4-Factor Sector Score, with 51.4 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Drug Manufacturers - General, all 16 compared on one page.

Sanofi is the 12th largest of 17 Drug Manufacturers - General companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Novo Nordisk A/S, Pfizer Inc. and Bristol-Myers Squibb Company. Just below it: GSK plc, Biogen Inc. and Grifols, S.A.

Drug Manufacturers - General companies close in size

9. Novo Nordisk A/S $198.3 billion
10. Pfizer Inc. $175.4 billion
11. Bristol-Myers Squibb Company $131.2 billion
12. Sanofi $118.4 billion
13. GSK plc $107.2 billion
14. Biogen Inc. $37.6 billion
15. Grifols, S.A. $7.5 billion

All 17 Drug Manufacturers - General companies, largest first

Companies close in size in other industries

134. Petróleo Brasileiro S.A. - Petrobras $119.4 billion · Oil & Gas Integrated
135. BP p.l.c. $118.9 billion · Oil & Gas Integrated
136. Sanofi $118.4 billion
137. The Bank of Nova Scotia $117.3 billion · Banks - Diversified
138. PDD Holdings Inc. $116.9 billion · Internet Retail

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.